2024-513716-95-00
Active, not recruiting
Phase 1
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Nec Oncoimmunity AS
- Enrollment
- 6
- Locations
- 2
- Status
- Active, not recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
No summary available.
Investigators
Project Leader
Scientific
Nec Oncoimmunity AS
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers2024-515124-36-00Integrative Research Laboratories Sweden AB12
Not yet recruiting
Phase 1
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.2023-510356-23-00Novartis Pharma AG76
Recruiting
Not Applicable
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNCT07266493Shanghai Zhongshan Hospital26
Recruiting
Phase 3
Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis2022-501788-41-00Abbvie Deutschland GmbH & Co. KG40
Not yet recruiting
Not Applicable
A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy SubjectsNCT07264335Guangdong Hengrui Pharmaceutical Co., Ltd160